ASF1057

Astion Pharma A/S · Phase 3 active Small molecule

ASF1057 is an investigational therapeutic targeting immune or inflammatory pathways in development by Astion Pharma.

At a glance

Generic name	ASF1057
Sponsor	Astion Pharma A/S
Modality	Small molecule
Phase	Phase 3

Mechanism of action

Limited public information is available on ASF1057's specific mechanism of action. As a Phase 3 asset from Astion Pharma, it is likely a targeted small molecule or biologic designed to modulate a specific disease pathway, but the exact molecular target and therapeutic mechanism require access to clinical trial data or company disclosures.

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Efficacy and Safety of ASF1057 in the Treatment of Seborrhoeic Dermatitis (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

ASF1057 CI brief — competitive landscape report
ASF1057 updates RSS · CI watch RSS
Astion Pharma A/S portfolio CI